Definium Therapeutics, Inc. (DFTX) vs Doximity, Inc. (DOCS)
A side-by-side comparison of Definium Therapeutics, Inc. and Doximity, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
DFTX
Definium Therapeutics, Inc.
$35.12HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
DOCS
Doximity, Inc.
$28.45HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
Total return — DFTX vs DOCS
growth of $100 · dividends reinvested · last 5yDFTX -32.0% (-7.4%/yr)DOCS -46.1% (-11.6%/yr)DFTX compounded faster over this window
DFTX DOCS
DFTX vs DOCS: by the numbers
- •DOCS is the larger company ($5.32B vs $4.66B market cap).
- •DOCS is profitable (25.48% net margin) while DFTX runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | DFTX | DOCS |
|---|---|---|
| P/E ratio | N/A | 33.47 |
| Forward P/E | N/A | 21.12 |
| PEG ratio | N/A | 0.64 |
| P/S ratio | N/A | 8.12 |
| P/B ratio | 5.07 | 5.81 |
| EV / EBITDA | N/A | 23.90 |
| FCF yield | N/A | 5.62% |
Profitability
| Metric | DFTX | DOCS |
|---|---|---|
| Gross margin | 0.00% | 88.07% |
| Operating margin | 0.00% | 29.60% |
| Net margin | 0.00% | 25.48% |
| ROE | -38.51% | 18.24% |
| ROIC | -23.81% | 15.35% |
Growth (annualized)
| Metric | DFTX | DOCS |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 21.94% |
| EPS CAGR (5Y) | N/A | 54.32% |
| FCF CAGR (5Y) | N/A | 23.75% |
| Total return CAGR (5Y) | 1.43% | -18.23% |
Frequently asked
- Is DFTX or DOCS more profitable?
- DOCS runs the higher net margin — DFTX at 0.00% versus DOCS at 25.48%.
- How have DFTX and DOCS total returns compared?
- Over the past 5 years, DFTX delivered 1.43% and DOCS delivered -18.23% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Doximity P/E ratioDefinium Therapeutics ROEDoximity ROEDefinium Therapeutics operating marginDoximity operating marginDefinium Therapeutics revenue growthDoximity revenue growthDefinium Therapeutics free cash flowDoximity free cash flow
Definium Therapeutics & Doximity appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.